Hemophagocytic lymphohistiocytosis caused by tislelizumab
10.3760/cma.j.cn114015-20220808-00726
- VernacularTitle:替雷利珠单抗致噬血细胞综合征
- Author:
Anxia LI
1
;
Shuyi XUE
;
Bingqing ZHAO
;
Yaodong PING
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Publication Type:Journal Article
- Keywords:
Lymphohistiocytosis, hemophagocytic;
Immune checkpoint inhibitors;
Serum ferritin;
Tislelizumab;
Immune-related adverse events
- From:
Adverse Drug Reactions Journal
2023;25(11):700-702
- CountryChina
- Language:Chinese
-
Abstract:
A 49-year-old male patient with primary hepatocellular carcinoma was treated with donafenib combined with tislelizumab. After 2 cycles of treatments, he developed persistent fever, poor appetite, fatigue, decreased white blood cells, hemoglobin, platelets, and fibrinogen, and significant increase of serum ferritin(91 501 μg/L) and splenomegaly. Hemophagocytic lymphohistiocytosis was diagnosed, which was consideredto be caused by tislelizumab. He received intravenous infusion of methylprednisolone 60 mg/d for 4 days, 40 mg/d for 7 days, 28 mg/d for 5 days, and at last, oral prednisone 35 mg/d was given, with dose reduction to discontinuation within 4-6 weeks. During the treatment, his laboratory tests results were improved. The patient did not use tislelizumab again and donafenib treatment was reused, and the above symptoms did not recur.
